News - Vivalis, Metabolics

Filter

Current filters:

VivalisMetabolics

Popular Filters

1 to 25 of 108 results

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

27-03-2014

Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

31-01-2014

Privately-held US company Edison Pharmaceuticals has entered into a new strategic alliance valued up…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589LicensingMetabolicsNeurologicalPharmaceutical

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Orexigen has another go at FDA approval of obesity drug Contrave

Orexigen has another go at FDA approval of obesity drug Contrave

12-12-2013

US biopharma company Orexigen Therapeutics is having another stab at gaining approved for its weight-loss…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulation

Mixed FDA advisory panel votes on Bristol-Myers and AstraZeneca's metreleptin

Mixed FDA advisory panel votes on Bristol-Myers and AstraZeneca's metreleptin

12-12-2013

In an 11 to one vote yesterday, the US Food and Drug Administration’s Endocrinologic and Metabolic…

AstraZenecaBristol-Myers SquibbMetabolicsmetreleptinNorth AmericaPharmaceuticalRare diseasesRegulation

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

Orexigen to resubmit US NDA for obesity drug Contrave

26-11-2013

Along with presenting new data for its weight loss drug candidate Contrave (naltrexone SR and bupropion…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulationResearchTakeda Pharmaceuticals

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Zafgen’s obesity treatment beloranib demonstrates weight loss in Phase II results

Zafgen’s obesity treatment beloranib demonstrates weight loss in Phase II results

18-11-2013

Privately-owned US biopharmaceutical company Zafgen has announced final efficacy and safety data from…

beloranibMetabolicsNorth AmericaPharmaceuticalResearchUSAZafgen

NPS Pharma files BLA for Natpara in hypoparathyroidism

25-10-2013

US biotech company NPS Pharmaceuticals has submitted its Biologic License Application to the US Food…

BiotechnologyMetabolicsNatparaNorth AmericaNPS Pharmaceuticals

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Orexigen resubmits obesity drug application in Europe

Orexigen resubmits obesity drug application in Europe

04-10-2013

Having experienced significant delays in gaining approval for its weight-loss drug, Orexigen Therapeutics…

ContraveEuropeMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Sanofi reaches deal in rimonabant lawsuit

Sanofi reaches deal in rimonabant lawsuit

23-09-2013

French drug major Sanofi (Euronext; SAN) has reached a $40 million settlement in a US lawsuit accusing…

MetabolicsNorth AmericaRegulationSanofi

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Pfizer links with academia for obesity and diabetes research

14-08-2013

As part of a new collaboration, the USA's Sanford-Burnham Medical Research Institute at Lake Nona revealed…

DiabetesMetabolicsPfizerPharmaceuticalResearch

Orexigen updates on obesity drug filing plans

08-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) yesterday (August 7) announced its plan to…

BiotechnologyContraveEuropeFinancialMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Plandai's upcoming weight loss study primed to outperform competing trials, say analysts

05-08-2013

With a product that likely has the highest nutrient absorption rate into the bloodstream (bioavailability)…

BiotechnologyMetabolicsPhytofarePlandai BiotechnologyResearch

1 to 25 of 108 results

Back to top